Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Fulvestrant
Sponsor: ETOP IBCSG Partners Foundation
Collaborators: Breast International Group